Patients using Accolade, Proponent, Essentio, Altrua 2 Standard Life and Altrua 2 Extended Life pacemakers, as well as Visionist and Valitude cardiac resynchronization therapy pacemakers, may need to have their devices replaced earlier than anticipated, according to the FDA’s Dec. 16 alert.
Two deaths have been reported in association with these devices, according to Boston Scientific.
The FDA recommends providers monitor patients using these pacemakers. If a patient exhibits symptoms that suggest the device may have initiated safety mode, surgery should be scheduled to replace the device.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
